Positive Ph 1/2 Data for GT-30 Trial of Personalized Therapeutic Cancer Vaccine Announced May 15, 2024
Higher AML Complete Remission (CR) Rates and Significant Durability Reported with Additional Interim Subject Data May 15, 2024
Initial Data from Investigator-Initiated Ph 2 Trial of ZYNLONTA® in Patients with R/R MZL Announced May 14, 2024
FAILED TRIAL: Ph 3 CheckMate -73L trial did not meet primary endpoint of PFS in unresectable, locally advanced stage III NSCLC May 14, 2024
FAILED TRIAL: Pivotal Ph 3 Study of Uproleselan in R/R AML patients did not meet primary endpoint of OS in the intent-to-treat population May 14, 2024
Ph 3 KEYNOTE-811 Trial Met Dual Primary Endpoint of OS as 1L Treatment in Patients With HER2+ve Advanced Gastric/GEJ Adenocarcinoma May 7, 2024
Stenoparib Shows Clear Clinical Benefit and Achieves Significant Milestone with Early Conclusion of Ph 2 Trial in Advanced Ovarian Cancer May 7, 2024
Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer May 7, 2024
TAR-200 monotherapy shows greater than 80% complete response rate in patients with high-risk NMIBC May 7, 2024
Positive Ph 2 Preliminary Data of SLS009 in R/R AML Achieving a 100% Response Rate in Patients with ASXL1 Mutation at the Optimal Dose Level Announced May 7, 2024
Calquence combo regimen demonstrated statistically significant and clinically meaningful PFS improvement in 1L MCL in ECHO Ph 3 trial May 7, 2024
Ph 2 data for ERLEADA + ADT after radical prostatectomy in patients with high-risk localized prostate cancer show 100% biochemical free recurrence rate more than 2 years post-surgery May 7, 2024
Results from ATLAS Showing Robust UGN-102 Durability of Response in New and Recurrent Low-Grade Intermediate-Risk NMIBC Announced May 7, 2024
Positive OS Results of Anktiva Combined With Checkpoint Inhibitors in NSCLC Announced; Meeting Scheduled with FDA to Discuss Registration Path for ANKTIVA in Lung Cancer May 1, 2024
Enhertu demonstrated statistically significant and clinically meaningful PFS improvement in HR+ve, HER2-low metastatic breast cancer following one or more lines of endocrine therapy in DESTINY-Breast06 Ph 3 trial May 1, 2024
First Dose Level found to be Generally Well-Tolerated in Ph 1b/2 Study of Ampligen and Imfinzi Combination for Late-Stage Pancreatic Cancer May 1, 2024
Imfinzi + chemo doubled OS rate at 3 years for patients with advanced biliary tract cancer in TOPAZ-1 Ph 3 trial April 23, 2024
EBMT 2024: Iomab-B Overcomes High-Risk TP53 Mutation Resulting in Significant OS Improvement in R/R AML Patients April 23, 2024
Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen + Pembrolizumab for the Treatment of Recurrent Ovarian Cancer Announced April 16, 2024
